Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EUDA Health Holdings Limited filings document the company as a Nasdaq-listed foreign private issuer operating a Singapore-based healthcare business focused on non-invasive, preventive and longevity-oriented services in Asia. Form 6-K reports disclose business updates involving stem cell and cellular therapy arrangements, commercial distribution rights, and related healthcare platform expansion.
The filing record also covers capital-structure and governance matters, including ordinary share offerings under a Form F-3 registration statement, warrant issuances, amendments, repurchase and cancellation, a reverse stock split, Nasdaq market-value compliance notices, and amendments to the company's BVI constitutional documents.
Euda Health Holdings Limited reports that it has terminated its at-the-market equity offering program and the related At The Market Offering Agreement with Chardan Capital Markets, LLC. The program had previously allowed sales of ordinary shares with an aggregate offering price of up to $10.0 million, but this capacity had been reduced to zero and no ordinary shares were sold. All related prospectus supplements are also terminated as of the date of this supplement. The company’s ordinary shares trade on the NASDAQ Capital Market under the symbol EUDA, and the closing price was $15.30 on July 21, 2026.
EUDA Health Holdings Limited, a British Virgin Islands company listed on Nasdaq, has filed an amended Form F-3 to register the resale of up to 947,963 ordinary shares. These consist of 500,000 shares issued under a Simple Agreement for Future Tokens with QB Limited, 440,657 shares held by affiliates, and 7,306 shares issuable from 292,250 warrants held by a significant shareholder. EUDA is not selling shares and will receive no proceeds from these resales, though it will bear registration costs.
EUDA distributes non-invasive healthcare products and services in Singapore, Malaysia and China, but currently derives most revenue from property management services while building a wellness-focused business. It acquired CK Health in 2024 and is developing an integrated digital health and rewards platform that will use QB Utility Tokens as a loyalty medium; EUDA purchased 16 million tokens for internal platform use but does not control their issuance or market trading.
The company reports recurring losses, a going-concern explanatory paragraph, a working capital deficit, and a material weakness in internal control over financial reporting. It expects to need additional external financing and highlights extensive risks around its distribution model, third-party manufacturers, token integration, regulatory changes, and potential PFIC status.
EUDA Health Holdings Limited filed an amendment to a Form F-3 registration statement to register up to 947,963 ordinary shares for resale by identified selling shareholders.
The 947,963 Shares consist of 500,000 shares issued under the QB Agreement, 440,657 shares held by affiliates, and 7,306 Warrant Shares issuable upon exercise of 292,250 warrants at an exercise price of $230.00 per share. The company will not receive proceeds from sales by the selling shareholders. Ordinary shares outstanding after this offering are stated as 3,001,631.
EUDA Health Holdings filed a prospectus supplement to amend its prior ATM registration, reducing the maximum aggregate offering price to $10.0 million and suspending further sales under the ATM Agreement. The company states that no ordinary shares have been sold under the ATM Agreement as of the date of this Supplement. The company notified the manager on June 5, 2026 of its intent to terminate the ATM Agreement; the termination becomes effective 30 business days after that notice per the agreement. The supplement notes the Nasdaq closing price of the ordinary shares was $15.50 on June 11, 2026.
EUDA Health Holdings Limited is suspending and terminating its at-the-market equity offering program with Chardan Capital Markets LLC. The company had the ability to offer and sell up to $10,000,000 of ordinary shares under an At The Market Offering Agreement and related prospectus supplements.
EUDA sent a termination notice for the ATM Agreement on June 5, 2026, with termination to take effect on July 22, 2026 after a 30-business-day period. The ATM Offering has been suspended effective June 10, 2026, and EUDA plans to file a prospectus supplement reducing the number of shares offered to zero. As of this report, no ordinary shares have been sold under the ATM program.
EUDA Health Holdings Ltd reports an amended Schedule 13G showing beneficial ownership by Tan Meng Dong (James) and 8i Capital Limited. Mr. Tan beneficially owns 459,130 ordinary shares, equal to 15.3% of the outstanding ordinary shares; this total includes 340,631 shares held directly, 111,193 shares held by 8i Capital Limited, and 7,306 shares underlying warrants. The filing states 2,994,325 ordinary shares outstanding as of May 22, 2026. The statement notes that Mr. Tan is sole shareholder and director of 8i Capital Limited and that the parties filed a Joint Filing Agreement to report ownership jointly.
EUDA Health Holdings Ltd Schedule 13G reports that Zhang Xin beneficially owns 295,000 ordinary shares, representing 9.85% of the class. The filing states shares outstanding were 2,994,325 ordinary shares as of May 22, 2026.
The filing lists sole voting and sole dispositive power over the 295,000 shares. The document is a passive ownership disclosure under Schedule 13G and does not describe transactions or transfers within the excerpt.
EUDA Health Holdings Limited has expanded its Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, a premium beauty mask developed by Chemokine Pte Ltd. EUDA holds exclusive global distributorship rights for Helixé products from Chemokine.
The Regenixé Mask uses iPSC-derived skin stem cell secretome and cellulose mask technology, aimed at supporting skin hydration, brightening, and overall recovery. EUDA plans to leverage its existing distribution networks and wellness partnerships in Malaysia and China to drive sales across the Asia-Pacific region.
Management cites industry research indicating the global face mask market could reach about US$9.08 billion by 2031, with Asia-Pacific as a leading region. This launch aligns with EUDA’s broader strategy in non-invasive, preventive healthcare and longevity-focused consumer products in Asia.
EUDA Health Holdings Limited reported that it has regained compliance with the Nasdaq Capital Market’s continued listing requirements related to market value. Nasdaq had previously notified EUDA on April 23, 2026 that its Market Value of Listed Securities was below the required $35 million for 32 consecutive business days under Nasdaq Listing Rule 5550(b)(2). A subsequent Nasdaq notice on May 28, 2026 confirmed that EUDA’s Market Value of Listed Securities was $35 million or greater for ten consecutive business days from May 13 to May 27, 2026, restoring the Company’s compliance with the MVLS standard.
EUDA Health Holdings Limited filed a Form F-3 prospectus to register for resale up to 947,963 ordinary shares, consisting of 500,000 shares issued under a SAFT with QB Limited, 440,657 shares held by affiliates and 7,306 Warrant Shares issuable upon exercise of 292,250 warrants. The company will not receive proceeds from sales by the selling shareholders. The prospectus states 2,994,325 ordinary shares outstanding as of May 22, 2026 and discloses a Nasdaq MVLS deficiency (requirement: $35,000,000) with an April 23, 2026 notice and an October 20, 2026 cure deadline.
The filing also discloses going-concern commentary (net loss $2.8M in 2025, cash ~$0.3M, negative working capital ~$4.8M as of December 31, 2025), identification of a material weakness in internal control, and plans to register resale of shares issued under a token SAFT. The registration permits the listed selling shareholders to resell their shares from time to time; timing and amounts are at the selling shareholders’ discretion.